Evan Y. Yu, MD

Evan Y. Yu, MD

Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4830
Seattle, WA 98109-1023

Admin Contact

Joanna Daya

Specialty / Expertise

Genitourinary oncology (Prostate, bladder, and testicular cancers)

Research Interests

  • Bone health (Cancer treatment induced bone loss, bone metastases, bone biomarkers, molecular imaging of bone)
  • Novel therapeutics

Current Research Projects

Chair for a cooperative group study within the American College of Radiology Imaging Networks and the Dept. of Defense Prostate Cancer Clinical Trials Consortium to evaluate Sodium Fluoride PET imaging as a response biomarker for men with metastatic castration resistant prostate cancer selected for treatment with dasatinib.

Chair for an upcoming Southwest Oncology Group (SWOG) randomized phase 2 clinical trial of combined androgen deprivation therapy or combined androgen deprivation therapy with IMC-A12 (monoclonal antibody to IGF-IR) for men with newly diagnosed metastatic hormone therapy naive prostate cancer.

Effects of SRC kinase inhibition on prostate cancer and bone - Steering committee member for the randomized phase 3 clinical trial of docetaxel plus dasatinib vs. docetaxel plus placebo in men with metastatic castration resistant prostate can


Dr. Yu received his medical degree at the University of Washington School of Medicine. He performed his internship and residency at Harvard Medical School and the Brigham and Women’s Hospital. He went on to do oncology fellowship training at Harvard Medical School’s combined program at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He had extended post-doctoral laboratory training in William C. Hahn’s laboratory. He now specializes in clinical and translational prostate cancer research.

Selected Publications

Yu EY, Massard C, Gross M, Carducci M, Culine S, Hudes G, Posadas E, Sternberg C, Wilding G, Trudel G, Paliwal P, Fizazi K.  Phase 2 study of once-daily dasatinib in patients with metastatic castration-resistant prostate cancer.  Ann Oncol (Submitted Apr. 2010).

Ermoian R, Kalina R, Yu EY, Parvathaneni U.  Ocular prostate cancer metastasis treated with external beam radiation.  Retin Cases Brief Rep (Submitted Jan. 2010).

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA.  A randomized phase 2 study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration resistant prostate cancer.  J Clin Oncol (Submitted Nov. 2009, Revised Feb. 2010).

Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Duration of first off treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.  J Clin Oncol 2010; epub April 26, 2010.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.  Lancet 2010; epub April 15, 2010

Yu EY, Wilding G, Posadas M, Gross M, Culine S, Massard C, Morris M, Hudes GR, Calabro F, Trudel GC, Sternberg CN.  Phase 2 study of dasatinib in patients with metastatic castration-resistant prostate cancer.  Clin Cancer Res.

Perez F, Fligner C, Yu EY. Rapid clinical deterioration and leukemoid reaction following  treatment of urothelial carcinoma of the bladder: possible role of granulocyte-colony stimulating factor.  J Clin Oncol 2009; 27(34):e215-217.

Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E.  Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.  Br J Cancer 2009; 101:263-268.

Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn 2007; 7(5):659-672.

Yu EY, Hahn WC. Genetic alterations in prostate cancer. Clin Prostate Cancer 2005; 3:220-229.

Yu EY, Hahn WC. The origin of cancer. In: Farid NR, editor. Molecular basis of thyroid cancer. Norwell: Kluwer Academic Publishers, 2004, Chapter 1:1-22.

Yu EY, Hahn WC, George DJ, Kantoff PW. Opportunities for targeted molecular therapy for prostate cancer. In: Klein EA, editor. Management of prostate cancer. Totowa: Humana Press, 2004, Chapter 35:631-652.

Yu EY, Oh WK. Neoadjuvant therapy for high-risk localized prostate cancer. Curr Oncol Rep 2003; 5:250-257.

Masutomi K,* Yu EY, *Khurts S, Ben-Porath , Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn WC. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114:241-253.  *These authors contributed equally to this work.

*Stewart SA, *Dykxhoorn DM, *Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen ISY, Hahn WC, Sharp PA, Weinberg RA, Novina CD.  Lentivirus-delivered stable gene silencing by RNAi in primary cells.  RNA 2003; 9:493-501.  *These authors contributed equally to this work.

Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D’Amato R, Folkman J, Mulligan RC.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.  Proc Natl Acad Sci 2001; 98:4605-4610.

Yu EY, Meyer GE, Brawer MK.  The relation of p53 nuclear accumulation and angiogenesis in human prostatic carcinoma.  Prostate Cancer Prostatic Dis 1997; 1:39-44.

Last updated: February 2011